BAFNAPHARM

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on February 13, 2020.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on February 13, 2020.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on November 13, 2019.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on August 10, 2019.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on May 27, 2019.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on February 08, 2019.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on November 13, 2018.We would like to inform you that the Board at its meeting held on today approved the un-audited financial results for the quarter / half year ending 30th September 2018. Please find attached the un-audited financial results for quarter / half year ending 30th September 2018 along with the Limited Review Report obtained from the statutory auditor of the Company.The meeting commenced at 3.00 PM and concluded at 6.45 P.M

Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on September 05, 2018.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on August 13, 2018.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on May 28, 2018.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on February 12, 2018.1. Considered and approved Unaudited Financial Statements for the quarter and Nine months period ended 31st December, 2017.2. Allotment of Equity Shares on preferential basis to the share warrant holders, as the entire warrant money has been received

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on November 10, 2017.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on October 06, 2017.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 08, 2017.1. Approval of Directors report2. Fixing of date, place, time of 22nd AGM.3. Fixing of Book Closure for 22nd AGM4. Fixing of Cut-off Date for voting5. To recommend the appointment of Statutory Auditor of the Company.6. To recommend the re-appointment of Managing Director of the Company 7.To recommend the re-appoint of Whole time Director of the Company.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 08, 2017.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 27, 2017.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on March 14, 2017.

Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company was held on January 07, 2017, In the meeting, the following matters were decided by the Board: Considered and decided to issue 80,00,000 share warrants on preferential basis to promoter and non-promoter group at such price as may be arrived at in accordance with SEBI (ICDR) Regulations, 2009, subject to the approval of the members of the Company through Postal Ballot by way of passing a special resolution under section 42 and 62 of the Companies Act, 2013 and other necessary approvals. It was fur

Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company was held on January 04, 2017, where it was decided to withdraw entire preferential issue of 40,00,000 share warrants and in-principle application filed with the Stock Exchanges.

Bafna Pharmaceuticals Limited has informed the Exchange the Outcome of Board Meeting held on 11th November, 2016

Bafna Pharmaceuticals Limited has informed the Exchange regarding the outcome of the Board of Directors of the Company at their meeting held on February 11, 2016: 1. Appointment of Chief Financial Officer.

Bafna Pharmaceuticals Limited has informed the Exchange regarding outcome of the Board Meeting held on May 29, 2015

Bafna Pharmaceuticals Limited has informed the Exchange that at the Board Meeting held on July 21, 2014 the Board of Directors of the Company have decided for selling majority stake of branded generic business to Strides Arcolab Limited and in this connection entered into agreement(s) with Strides Arcolab Limited on July 21, 2014. Further, the Company has submitted a copy of press release dated July 21, 2014 titled "BAFNA PHARMACEUTICALS TO SELL MAJORITY STAKE OF BRANDED GENERICS BUSINESS TO STRIDES ARCOLAB".

Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its Board Meeting held on May 30, 2014, has not proposed dividend for FY ended March 31, 2014.

Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on August 10, 2013 has transacted the following: (1) Appointment of Mr. Kamlesh Kumar as Additional Director (Non-Executive Independent Director). And further Mr. Kamlesh Kumar was made as a member of Audit Committee. (2) Cancelled 25,00,000 convertible Warrants allotted on January 13, 2012 for nonpayment of balance money within 18 months and forfeited the 25% (application) money paid at the time of allotment of warrants. (3) Proposed the appointment of Mr. Kamlesh Kumar, Inde

Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 22, 2013, have: (1) Accepted the resignation of Mr. A. Sahasranaman, Independent Director with immediate effect, who has resigned due to personal commitments. Board placed on record their appreciation for the contribution made & valuable advices provided by him during him tenure. (2) Re-appointed Statutory Auditor subject to approval of shareholders in the forthcoming Annual General Meeting.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of the Board Meeting held on December 26, 2012.